Ligand Pharmaceuticals (LGND) Preferred Stock Liabilities (2011 - 2012)

Ligand Pharmaceuticals has disclosed Preferred Stock Liabilities across 2 years of filings, most recently posting $8.3 million for Q1 2012.

• Preferred Stock Liabilities for Q1 2012 came in at $8.3 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2012 was $8.3 million (changed N/A YoY), and the FY2011 annual result was $8.3 million, changed N/A from the prior year.
• Preferred Stock Liabilities came in at $8.3 million for Q1 2012 at Ligand Pharmaceuticals, down from $8.3 million in the prior quarter.
• In the past five years, Preferred Stock Liabilities ranged from a high of $8.3 million in Q4 2011 to a low of $8.3 million in Q1 2012.